Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (68 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > An elite team of influencers ...
View:
Post by ScienceFirst on May 03, 2022 12:04pm

An elite team of influencers ...

One more proof:

Dr. Kamat and Dr. Peter Black:

Bladder Cancer: A practical guide



And this, April 19, 2022:

UroToday - Discussing Bladder Cancer with Harvard's Dana Farber (Dr. Alicia Morgans), MD-Anderson (Dr. Kamat) and Univ. of British-Columbia (Dr. Peter Black)


 

________________________

And just for the NMIBC indication, Roger has been able to attract top guns:

- Dr. Kamat:

... President - International Bladder Cancer Network (IBCN)
... BCAN Scientific Advisory Board
... advisor to many pharmas on NMIBC topics

- Dr. O'Donnell:

... BCAN Scientific Advisory Board
... advisor to many pharmas on NMIBC topics

- Dr. Peter Black:

... B-C University Ph. 2b site
... Chair - Medical Advisory & Research Board - Bladder Cancer Canada  
... Secretary General - International Bladder Cancer Network (IBCN))

- Dr. Kassouf :

... McGill Univ. Ph. 2b site
... Past Chair - Medical Advisory & Research Board - Bladder Cancer Canada for 10y

- Dr. Kulkarni:

... UHN. Ph. 2b site
... Ph. 2b lead investigator
... Vice-Chair - Medical Advisory & Research Board - Bladder Cancer Canada
Comment by ScienceFirst on May 03, 2022 7:51pm
Dr. Kamat and Dr. Peter Black will be aware of the TLD-1433 alternative. Understanding the mechanisms driving recurrence is critical to improve outcomes for patients with NMIBC ___________________________ ScienceFirst - (5/3/2022 12:04:36 PM) An elite team of influencers ... One more proof: Dr. Kamat and Dr. Peter Black: Bladder Cancer: A ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 68 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250